Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd-Chiari Syndrome

Gastroenterology

Volumn 130, Issue 7, 2006, Pages 2031-2038

  Patel, Raj K ^a   Lea, Nicholas C ^a   Heneghan, Michael A ^a   Westwood, Nigel B ^a   Milojkovic, Dragana ^a   Thanigaikumar, Murugaiyan ^a   Yallop, Deborah ^a   Arya, Roopen ^a   Pagliuca, Antonio ^a   Gäken, Joop ^a   Wendon, Julia ^a   Heaton, Nigel D ^a   Mufti, Ghulam J ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; JANUS KINASE;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BONE MARROW; BUDD CHIARI SYNDROME; CELL CULTURE; CHILD; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ERYTHROID PRECURSOR CELL; FEMALE; GENE MUTATION; HEMATOCRIT; HUMAN; MALE; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SCREENING; THROMBOCYTOPENIA;

EID: 33744505451     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.04.008     Document Type: Article

References (35)

1. Ludwig J., Hashimoto E., McGill D.B., et al. Classification of hepatic venous outflow obstruction. ambiguous terminology of the Budd-Chiari syndrome. Mayo Clin Proc 65 (1990) 51-55
2. Hadengue A., Poliquin M., Vilgrain V., et al. The changing scene of hepatic vein thrombosis. recognition of asymptomatic cases. Gastroenterology 106 (1994) 1042-1047
3. Bismuth H., and Sherlock D.J. Portosystemic shunting versus liver transplantation for the Budd-Chiari syndrome. Ann Surg 214 (1991) 581-589
4. Narayanan Menen K.V., Shah V., and Kamath P. The Budd-Chiari Syndrome. N Engl J Med 350 (2004) 578-585
5. Denninger M.H., Chait Y., Casadevall N., et al. Cause of portal or hepatic vein thrombosis in adults. the role of multiple concurrent factors. Hepatology 31 (2000) 587-591
6. Valla D., Casadevall N., Lacombe C., et al. Primary myeloproliferative disorder and hepatic vein thrombosis. a prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari Syndrome. Ann Intern Med 103 (1985) 329-334
7. Primignani M., Martinelli I., and Bucciarelli P. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 41 (2005) 603-608
8. Wasserman L. The management of Polycythemia Vera. Br J Haematol 21 (1971) 371-376
9. Pearson T.C. Evaluation of diagnostic criteria in polycythemia vera. Semin Hematol 38 Suppl 2 (2001) 21-24
10. Vardiman J.W., Harris N.L., and Brunnung R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
11. Murphy S. Therapeutic dilemmas. balancing the risks of bleeding, thrombosis and leukemic transformation in myeloproliferative disorders (MPD). Thromb Haemost 78 (1997) 622-626
12. Pagliuca A., Mufti G.J., Janossa-Tahernia M., et al. In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis-possible evidence of an occult myeloproliferative state. Q J Med 76 (1990) 981-989
13. Valla D., Casadevall N., Lacombe C., et al. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 103 (1985) 329-334
14. Valla D., Casadevall N., Huisse M.G., et al. Aetiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology 94 (1988) 1063-1069
15. Muller E.W., De Wolf J.T., and Haagsma E.B. Portal hypertension as a presenting feature of a myeloproliferative disorder. Diagnosis and therapeutic dilemmas. Scand J Gastroenterol Suppl 200 (1993) 74-79
16. De Stefano V., Teofili L., Leone G., et al. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Haemost 23 (1997) 411-418
17. McNamara C., Juneja S., Wolf M., et al. Portal or hepatic vein thrombosis as the first presentation of a myeloproliferative disorder in patients with normal peripheral blood counts. Clin Lab Hematol 24 (2002) 239-242
18. Dudley J.M., Westwood N., Leonard S., et al. Primary polycythemia. positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoietin, interleukin 3 and alpha-interferon. Br J Haematol 75 (1990) 188-194
19. Dainiak N., Hoffman R., Lebowitz A.I., et al. Erythropoietin-dependent primary pure erythrocytosis. Blood 53 (1979) 1076-1084
20. Eridani S., Dudley J.M., Sawyer B.M., et al. Erythropoietic colonies in a serum-free system. results in primary proliferative polycythemia and thrombocythemias. Br J Haematol 67 (1987) 387-391
21. Lemoine F., Najman A., Baillou C., et al. A prospective study of the value of bone marrow erythroid progenitor cultures in polycythemia. Blood 68 (1986) 996-1002
22. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders. it all makes sense. Blood 105 (2005) 4258-4263
23. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases. Lancet 365 (2005) 1054-1061
24. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
25. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 434 (2005) 1144-1148
26. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790
27. Westwood N.B., Gruszka-Westwood A.M., Atkinson S., et al. Polycythemia vera. analysis of DNA from blood granulocytes using comparative genomic hybridisation. Haematologica 86 (2001) 464-469
28. Westwood N.B., and Pearson T.C. Diagnostic applications of haemopoietic progenitor culture techniques in polycythemias and thrombocythemias. Leukemia Lymphoma 22 Suppl 1 (1996) 95-103
29. Acharya J., Westwood N.B., Sawyer B.M., et al. Identification of latent myeloproliferative disease in patients with Budd-Chiari syndrome using X-chromosome inactivation patterns and in vitro erythroid colony formation. Eur J Haematol 55 (1995) 315-321
30. Cortelazzo S., Viero P., Finazzi G., et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8 (1990) 556-562
31. Pearson T.C., Botterill C.A., Glass U.H., et al. Interpretation of measured red cell mass and plasma volume in males with elevated venous PCV values. Scand J Haematol 33 (1984) 68-74
32. V617F mutation in essential thrombocythemia. clinical associations and long-term prognostic relevance. Br J Haematol 131 (2005) 208-213
33. Zeitoun G., Escolano S., Hadengue A., et al. Outcome of Budd-Chiari syndrome. a multivariate analysis of factors related to survival including portosystemic shunting. Hepatology 30 (1999) 84-89
34. Srinivasan P., Rela M., Prachalias A., et al. Liver transplantation for the Budd-Chiari syndrome. Transplantation 73 (2002) 973-977
35. Melear J.M., Goldstein R.M., Levy M.F., et al. Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders. Transplantation 74 (2002) 1090-1095